A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
A phase 2 trial of CYH33 in ovarian cancer, run by Haihe Biopharma Co., Ltd., active and no longer recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma is a phase 2 interventional study registered as NCT05043922 by Haihe Biopharma Co., Ltd., with 93 participants enrolled, started 2021-10-11 and due to reach its primary completion in 2024-07-31. Interventions recorded: CYH33.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Haihe Biopharma and the tag pipeline.
- TrialAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Shares Haihe Biopharma and the tag pipeline.
- TrialEvaluate the Safety and Clinical Activity of HH2853
Shares Haihe Biopharma and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.